Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

LeukoScreen AI-based leukemia detection in routine diagnostic blood smear data

Coordinator
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH, Germany
Runs
1 December 2023 to 31 May 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101113551

What the project is doing

In the project's own words, from its summary on CORDIS.

Acute promyelocytic leukemia is an extremely aggressive blood cancer where immediate diagnosis can determine life or death. The diagnostic state of the art is manual inspection of a patient’s blood smear under the microscope by trained cytologists. It is prone to human error and time consuming - a risk factor in notoriously understaffed laboratories. Supporting clinical decisions with AI will drastically increase diagnostic speed and accuracy, benefit patient survival, and free up valuable expert time.

This is particularly important for cytological and histological analysis, whose market size is expected to rise by a compounded annual growth rate of 14.7% in coming years. Yet, so far, the proof of concept that AI can be effectively employed for leukemia detection in routine diagnostics is missing. I will leverage the methodological advancements in deep learning and explainable AI, the skills of my ERC CoG funded research group, and the expertise and data of the Munich Leukemia Laboratory (MLL), the largest leukemia laboratory in Europe and my long standing industry partner.

Together, we will develop and implement LeukoScreen, an AI-based software to automatically identify and flag up acute leukemia cases from MLL’s routine laboratory input. This will decrease the diagnosis to treatment time of critical leukemia cases at reduced costs and staffing. Specifically, we will (i) deploy a real-world dataset from the routine input of the MLL, (ii) train and evaluate our algorithm for transparent decision making on routine diagnostic blood smears, (iii) quantify the gain in sensitivity, specificity, and speed by comparing LeukoScreen with the currently used manual workflow at MLL, and (iv) jointly develop a commercialization strategy for the exploitation of results.

This AI approach to support disease detection will save patients’ lives, change the paradigm of cytologic workflows, and create capacities in overburdened diagnostics.

Topics

Who is involved

OrganisationCityCountryRole
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyCoordinator
Mlli GmbHMunchenGermanyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI